Table 4.
Annual rates of site-specific invasive cancer cases other than breast and uterine cancer—NSABP STAR Trial (P-2)
| Site of cancer | Events, n | Rate per 1000 | RR† | RR (95% CI) | |||
|---|---|---|---|---|---|---|---|
| Tamoxifen | Raloxifene | Tamoxifen | Raloxifene | Difference* | |||
| Adrenal gland | 0 | 1 | 0 | 0.02 | −0.02 | — | — |
| Bone/cartilage/connective tissue | 3 | 4 | 0.05 | 0.06 | −0.01 | 1.32 | 0.22–8.98 |
| Buccal cavity and pharynx | 4 | 6 | 0.06 | 0.10 | −0.04 | 1.48 | 0.35–7.13 |
| Cervix | 3 | 0 | 0.05 | 0 | 0.05 | — | — |
| Colorectal | 48 | 45 | 0.78 | 0.72 | 0.06 | 0.93 | 0.60 to 1.42 |
| Esophagus | 2 | 0 | 0.03 | 0 | 0.03 | — | — |
| Eye | 1 | 1 | 0.02 | 0.02 | 0 | 0.99 | 0.01–77.48 |
| Gallbladder | 5 | 2 | 0.08 | 0.03 | 0.05 | 0.39 | 0.04–2.41 |
| Kidney | 14 | 21 | 0.23 | 0.34 | −0.11 | 1.48 | 0.72–3.15 |
| Larynx | 0 | 1 | 0 | 0.02 | −0.02 | — | — |
| Leukemia/other lymph/hemato | 60 | 53 | 0.97 | 0.85 | 0.12 | 0.87 | 0.59–1.28 |
| Liver | 7 | 2 | 0.11 | 0.03 | 0.08 | 0.28 | 0.03–1.48 |
| Lung, trachea, bronchus | 57 | 64 | 0.92 | 1.02 | −0.10 | 1.11 | 0.76–1.61 |
| Nasal/middle ear/sinuses | 1 | 1 | 0.02 | 0.02 | 0 | 0.99 | 0.01–77.48 |
| Nervous system | 9 | 10 | 0.15 | 0.16 | −0.01 | 1.10 | 0.40–3.05 |
| Other gyn | 2 | 2 | 0.03 | 0.03 | 0 | 0.99 | 0.07–13.62 |
| Ovary | 21 | 34 | 0.50 | 0.79 | −0.29 | 1.58 | 0.89–2.86 |
| Pancreas | 12 | 11 | 0.19 | 0.18 | 0.01 | 0.90 | 0.36–2.24 |
| Retroperitoneum | 7 | 4 | 0.11 | 0.06 | 0.05 | 0.56 | 0.12–2.22 |
| Skin | 25 | 24 | 0.40 | 0.38 | 0.02 | 0.95 | 0.52–1.73 |
| Small intestine | 0 | 2 | 0 | 0.03 | −0.03 | — | — |
| Spleen | 0 | 2 | 0 | 0.03 | −0.03 | — | — |
| Stomach | 5 | 1 | 0.08 | 0.02 | 0.06 | 0.20 | 0.004–1.76 |
| Thyroid gland | 18 | 32 | 0.29 | 0.51 | −0.22 | 1.76 | 0.96–3.32 |
| Urinary bladder | 15 | 12 | 0.24 | 0.19 | 0.05 | 0.79 | 0.34–1.81 |
| Site unspecified/unspecified nature | 15 | 19 | 0.24 | 0.30 | −0.06 | 1.25 | 0.60–2.64 |
| Secondary/uncertain | 4 | 5 | 0.06 | 0.08 | −0.02 | 1.23 | 0.27–6.22 |
Abbreviations: CI, confidence interval; gyn, gynecologic; hemato, hematopoietic; lymph, lymphatic; NSABP STAR, National Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.
*
Rate in the tamoxifen group minus rate in the raloxifene group.
†
Risk ratio for women in the raloxifene group compared with women in the tamoxifen group.